Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi PharmaTech Announces Outstanding Q3 Numbers

publication date: Nov 10, 2010
WuXi PharmaTech reported impressive Q3 results, showing that the Shanghai-based CRO is continuing to prosper on all fronts. The company said its revenues were 20% higher than the year-earlier quarter at $83.8 million, and non-GAAP net income rose 27% to $22.4 million. GAAP numbers were even higher as WuXi booked a $30 million breakup fee from Charles River Labs, which decided in Q2 not to proceed with its acquisition of WuXi PharmaTech. More details....

Stock Symbols: (NYSE: WX) (NYSE: CRL)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here